However, a fundamental paradigm shift occurred in the 2016 WHO classification, which emphasized molecular such as Isocitrate Dehydrogenase (IDH) mutation status and 1p/19q codeletion to improve diagnostic accuracy and prognostic stratification of gliomas [3]. This evidence concerns the gene IDH3A and central nervous system cancer.